Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › Efpeglenatide

Efpeglenatide

GLP-1 · s.c. · Hanmi

Data cut 12 November 2026 · page built 16 November 2026 · 0 trial arms · 1 trials with results · 1 registered trials · see on the pipeline board

Summary

Also known as
Hanmi / Sanofi
Mechanism
GLP-1
Route
s.c.
Company
Hanmi
Highest development stage
—
Status (as of data cut)
Positive CVOT (AMPLITUDE-O); development paused verify
Next milestone
—

Trial arms: weight, HbA1c and tolerability

No trial arms with extracted efficacy or tolerability data yet.

Outcome trials

Cardiovascular and kidney outcome trials

AMPLITUDE-O efpeglenatide 4/6 mg vs placebo · T2D + CVD/CKD · n = 4076 · 2021 verified

EndpointHR95 % CIEvents, drug vs controlStatus
3-point MACE primary
Primary MACE: first nonfatal MI, nonfatal stroke, or death from cardiovascular or undetermined causes
0.730.58–0.92189 vs 125verified
Cardiovascular death
Cardiovascular mortality
0.720.50–1.0375 vs 50verified
All-cause death
Total mortality (death from any cause)
0.780.58–1.06111 vs 69verified
Myocardial infarction
Myocardial infarction (fatal or non-fatal)
0.750.54–1.0591 vs 58verified
Stroke
Stroke (fatal or non-fatal)
0.740.47–1.1747 vs 31verified
Hospitalisation for heart failure
Hospitalization for heart failure (adjudicated; listed as 'Heart failure' in Table 2)
0.610.38–0.9840 vs 31verified
Kidney composite
Composite renal outcome (key secondary): incident macroalbuminuria (UACR >300 plus an increase of at least 30% from baseline), sustained eGFR decrease of at lea
0.680.57–0.79353 vs 250verified
Expanded MACE (MACE + revasc. + UA)
Expanded MACE: MACE (nonfatal MI, nonfatal stroke, death from CV or undetermined causes) plus coronary revascularization or hospitalization for unstable angina
0.790.65–0.96257 vs 158verified
New macroalbuminuria
Incident macroalbuminuria: UACR >300 mg/g (>33.9 mg/mmol) plus an increase in UACR of at least 30% from baseline
0.680.58–0.80348 vs 244verified
Coronary revascularisation
Coronary revascularization
0.930.69–1.26126 vs 66verified
Hospitalisation for unstable angina
Unstable angina (hospitalization for unstable angina, component of expanded MACE)
0.550.13–2.356 vs 4verified
Verbatim quotes (11)
  • 3-point MACE · Results, Trial Outcomes; Table 2
    189 of 2717 participants (7.0%) assigned to receive efpeglenatide and 125 of 1359 participants (9.2%) assigned to receive placebo had at least one MACE (...hazard ratio, 0.73; 95% CI, 0.58 to 0.92
  • Cardiovascular death · Table 2
    Cardiovascular mortality 75 (2.8) 1.5 50 (3.7) 2.1 0.72 (0.50–1.03)
  • All-cause death · Table 2
    Total mortality 111 (4.1) 2.2 69 (5.1) 2.8 0.78 (0.58–1.06)
  • Myocardial infarction · Table 2
    Myocardial infarction 91 (3.3) 1.9 58 (4.3) 2.4 0.75 (0.54–1.05)
  • Stroke · Table 2
    Stroke 47 (1.7) 1.0 31 (2.3) 1.3 0.74 (0.47–1.17)
  • Hospitalisation for heart failure · Table 2
    Heart failure 40 (1.5) 0.8 31 (2.3) 1.3 0.61 (0.38–0.98)
  • Kidney composite · Abstract; Table 2
    A composite renal outcome event ... occurred in 353 participants (13.0%) assigned to receive efpeglenatide and in 250 participants (18.4%) assigned to receive placebo (hazard ratio, 0.68; 95% CI, 0.57 to 0.79
  • Expanded MACE (MACE + revasc. + UA) · Table 2. Adjudicated First Events (footnote §)
    Expanded MACE composite outcome event§ 257 (9.5) 5.4 158 (11.6) 6.8 0.79 (0.65–0.96) 0.02
  • New macroalbuminuria · Table 2. Adjudicated First Events (footnote ¶)
    Incident macroalbuminuria 348 (12.8) 7.6 244 (18.0) 11.3 0.68 (0.58–0.80)
  • Coronary revascularisation · Table 2. Adjudicated First Events
    Coronary revascularization 126 (4.6) 2.6 66 (4.9) 2.8 0.93 (0.69–1.26)
  • Hospitalisation for unstable angina · Table 2. Adjudicated First Events
    Unstable angina 6 (0.2) 0.1 4 (0.3) 0.2 0.55 (0.13–2.35)

Registered trials (1)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
AMPLITUDE-O
Effect of Efpeglenatide on Cardiovascular Outcomes
CV outcomesPhase 3terminated2018-04 → 2020-124076MACE HR 0.73 (0.58–0.92)NCT03496298

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Efpeglenatide. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/efpeglenatide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.